phrykt

Iambic Therapeutics, Inc. (IAM): who owns it and who trades it

As of Nov 9, 2026, IAM insiders reported 1 purchase worth $11.5M in the last 12 months. The largest buyer was Evan Lockwood Rachlin (Director), with $11.5M.

Latest filing Nov 9, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, IAM insiders reported $11.5M of open-market purchases and $0 of sales.

Purchases, 12 months
$11.5M
1 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Oct 16, 2026
Filed Oct 19, 2026

Purchases and sales by month

$11.5M$11.5MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 16, 2026Evan Lockwood RachlinDirectorPurchase718,750$16.00$11.5MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Evan Lockwood RachlinDirector$11.5M–Oct 16, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

IAM short interest

1.06M IAM shares are sold short.

As of Oct 30, 2026, 1.06M IAM shares were sold short. At the average daily volume of 907,012 shares, buying them all back would take about 1.2 trading days (days to cover).

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.06M––907,0121.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Iambic Therapeutics company events

Iambic Therapeutics filed 1 report on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Oct 16, 2026.

  1. Oct 16, 2026RulesChanged its bylaws or articles. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named IAM in the last 120 days.

FiledHolderFormStake
Nov 9, 2026Qatar Investment Authority13G5.8%
Nov 9, 2026Qatar Investment Authority13G5.8%

Questions about Iambic Therapeutics, Inc. (IAM) stock

Are IAM insiders buying or selling?

In the last 12 months, IAM insiders reported 1 open-market purchase worth $11.5M and no sales. The latest trade was on Oct 16, 2026. See every trade.

What is the short interest in IAM?

As of Oct 30, 2026, 1.06M IAM shares were sold short. At the average daily volume of 907,012 shares, buying them all back would take about 1.2 trading days (days to cover). See the history.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.